AVEO Oncology (NSDQ:AVEO) announced that it appointed Mike Ferraresso as its new chief commercial officer.
Boston-based AVEO Oncology said in a news release that Feraresso will manage the company’s commercial strategy and operations, including the commercialization of Fotivda (tivozanib), a differentiated, oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI).
Fotivda is approved in the U.S. for treating adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.
“Directly on the heels of Fotivda’s approval, it is a pleasure to announce Mike’s appointment to chief commercial officer,” AVEO president & CEO Michael Bailey said in the release. “Mike’s hard work and dedication has played a crucial role in preparing for our evolution to a commercial organization. I look forward to working with Mike in his new role as we continue to execute on our mission of improving the lives of patients with cancer.”
Ferraresso most recently served as AVEO’s SVP of business analytics & commercial operations, having joined the company in December 2017. He is a veteran of more than 20 years in the commercial pharmaceutical and biotechnology space, having also held roles at Verastem, Infinity Pharmaceuticals, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics and Muro Pharmaceuticals.
“It is an honor to be taking on this new role at such an exciting time for the company,” Ferraresso said.. “I look forward to continuing to contribute to our evolution into a commercial organization.”
